PWM
VRTX icon

PRW Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

PRW Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-43
Closed -$8K – 658
2019
Q1 		$8K Hold
43
– – 0.01% 310
2018
Q4 		$6K Buy
+43
New +$7.45K 0.01% 359

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

PRW Wealth Management's VRTX Position: Q2 2019 in Review

PRW Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 43 shares — an estimated $8K sold.

PRW Wealth Management first reported a position in VRTX in Q4 2018 and held it in 2 quarters. The position peaked at $8K in Q1 2019. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

  • PRW Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • PRW Wealth Management sold 43 Vertex Pharmaceuticals shares in Q2 2019, an estimated $8K.
  • PRW Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • PRW Wealth Management's Vertex Pharmaceuticals position peaked at $8K in Q1 2019.
  • 716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on PRW Wealth Management's 13F filing for Q2 2019, filed 12 Aug 2019.